• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Global Blood Therapeutics Is Poised to Rally Further in the Months Ahead

GBT is dedicated to discovering, developing, and commercializing ways to treat blood disorders.
By BRUCE KAMICH
Dec 02, 2019 | 03:17 PM EST
Stocks quotes in this article: GBT

Global Blood Therapeutics (GBT) broke out to new highs last week and remains strong today. Let's check out the charts of this clinical-stage biopharmaceutical company. 

 
In this daily bar chart of GBT, below, we can see that prices made a straight up rally in November breaking above the June 2019 highs. Volume increased significantly on the rally giving us confirmation and support of the uptrend.
 
GBT is above the rising 50-day moving average line and the rising 200-day moving average line.
 
The daily On-Balance-Volume (OBV) line has soared sharply from November to tell us that buyers of GBT have been more aggressive.
 
The Moving Average Convergence Divergence (MACD) oscillator is also up strongly from a buy signal last month.   
 
 
 
In this weekly bar chart of GBT, below, we can see a bullish setup with prices and the indicators. Prices are in new high ground and above the rising 40-week moving average line.
 
The weekly OBV line has just made a new high for the long move up and confirms the price gains.
 
The trend-following MACD oscillator is crossing the zero line to the upside for a buy signal. 
 
 
In this first Point and Figure chart of GBT, below, we can see the uptrend and a relatively nearby price target of $75.  
 
  
In this second Point and Figure chart of GBT, below, we used weekly close only data and here a $110 price target is indicated.  
 
 
Bottom line strategy: Trade GBT from the long side risking below $64. $75 and then $110 are our price targets. 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals

More from Investing

Market Whips Up a Melt-up

James "Rev Shark" DePorre
Aug 12, 2022 4:21 PM EDT

This action is primarily caused by poor positioning, rather than a sudden improvement in fundamentals.

How Charged Up Is FuelCell?

Mark Sebastian
Aug 12, 2022 3:26 PM EDT

I see some energy here, at least for a trade.

Delisting of Chinese ADRs Is Part of the New Cold War

Jim Collins
Aug 12, 2022 2:00 PM EDT

The process of dealing with a delisted stock is painful for individual investors and impossible for many institutional investors.

Inflation May Be Slowing, but That Doesn't Mean the Fed Is

Maleeha Bengali
Aug 12, 2022 1:00 PM EDT

Investors are cheering the slowing pace of inflation's increase, but prices are still way up, which means the Fed is going to continue to take liquidity out of the system.

3 International Energy Stocks for Dividends And Growth

Bob Ciura
Aug 12, 2022 11:30 AM EDT

International companies often trade at discounts to their American counterparts, which can mean better value and better yields as well.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login